BioLineRx (BLRX) Change in Receivables (2024 - 2025)

BioLineRx (BLRX) recorded quarterly Change in Receivables of -$46000.0 in Q4 2025, down 158.97% quarter-over-quarter from $78000.0 in Q3 2025, and down 104.05% on a YoY basis from $1.1 million in Q4 2024.

BioLineRx (BLRX) Change in Receivables (2024 - 2025) Analysis & Trends

BioLineRx's Change in Receivables history runs 2 years deep, the most recent figure standing at -$46000.0 for Q4 2025.

  • In Q4 2025, Change in Receivables fell 104.05% year-over-year to -$46000.0; the TTM figure through Dec 2025 stood at $2.4 million (up 214.73% YoY), while the FY2025 annual figure was $2.4 million, up 214.73% from the prior year.
  • Change in Receivables was -$46000.0 for Q4 2025 at BioLineRx, down from $78000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.4 million in Q2 2025 to a low of -$2.5 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 22,529.00
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -39.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - -4.08 Mn
10 BioLineRx 227.63 Mn 211.90 Mn 154,000.00 -46,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -46,000.00
Dec 31, 2025 -46,000.00
Sep 30, 2025 78,000.00
Sep 30, 2025 78,000.00
Jun 30, 2025 1.39 Mn
Jun 30, 2025 1.39 Mn
Mar 31, 2025 1.01 Mn
Mar 31, 2025 1.01 Mn
Dec 31, 2024 1.14 Mn
Dec 31, 2024 1.14 Mn
Sep 30, 2024 -432,000.00
Sep 30, 2024 -432,000.00
Jun 30, 2024 -347,000.00
Jun 30, 2024 -347,000.00
Mar 31, 2024 -2.47 Mn
Mar 31, 2024 -2.47 Mn